Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-carnitine vs no treatment in nonalcoholic fatty liver disease
IRCT201610069014N121Phase 2Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of levocarnitine in metabolic dysfunction-associated steatotic liver disease (MASLD) (2 arms), sponsored by Hamadan University of Medical Sciences. Started Oct 2016; status: completed.
02
Drugs
levocarnitine
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on IRCT201610069014N121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT201610069014N121.